Wcm Investment Management Adds $903M in Teva Pharmaceutical Industries Limited ($TEVA)
Key Points
- Wcm Investment Management changed its Teva Pharmaceutical Industries Limited ($TEVA) stake by 191.4% last quarter, boosting to 40,820,600 shares worth $1.38 billion.
- Wall Street's consensus rating on $TEVA is Strong Buy and an average price target of $40.90.
- $TEVA last traded around $33.69.
Wcm Investment Management increased its position in Teva Pharmaceutical Industries Limited ($TEVA) by 191.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,820,600 shares of Teva Pharmaceutical Industries Limited after buying 26,813,522 shares during the quarter. Wcm Investment Management's holdings in Teva Pharmaceutical Industries Limited were worth $1.38 billion as of its most recent filing.
Teva Pharmaceutical Industries Limited ($TEVA) Stock
Teva Pharmaceutical Industries Limited Earnings
Analysts Set New Price Targets
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.